The Vibrating Capsule: Safety and Tolerability in Patients With Chronic Idiopathic Constipation
Neurogastroenterology & Motility · 2025-05 · 37 (5)
DOI: 10.1111/nmo.15004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 10.03.2025. Verfasst von Bryan F Curtin und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Digestive and Liver Diseases at Mercy Medical Center, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Constipation, Vibration. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic idiopathic constipation (CIC) remains a significant problem globally with increasing estimates for disease burden. In a Phase 3 placebo‐controlled trial, a novel treatment using the Vibrating Capsule was recently shown to be effective in treating patients with CIC. However, its safety and tolerability has not been described in detail.
Methods
We analyzed safety data from six trials encompassing the development of the Vibrating Capsule, including, dose‐ranging and pivotal studies. The incidence of adverse events, treatment discontinuation, tolerability and satisfaction were assessed. Key Results A total of 800 patients who took either an active Vibrating Capsule or a sham/placebo (non‐vibrating) but similar capsule from 6 studies were included in this post hoc analysis. The most common adverse gastrointestinal events were bloating (2.9%), abdominal pain (2.9%), nausea (2.3%) and diarrhea (1.9%). A sensation of vibration was reported by 11.7% of patients. The adverse events rates were low, and investigators categorized most of them as unrelated to treatment. There were no serious adverse events such as retention of therapeutic capsules and no patient stopped therapy or withdrew due to adverse effects. The majority of patients (83%) found the system convenient, with an overall treatment satisfaction rate of 71%. Conclusions and Inferences The Vibrating Capsule, a first in class treatment for CIC was found to be safe and well tolerated by patients in clinical trials. No patient discontinued treatment due to adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Institute of Digestive and Liver Diseases at Mercy Medical Center, Baltimore, Maryland, USA.
- Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas, USA.
- University of Michigan, Ann Arbor, Michigan, USA.
- Cleveland Clinic Digestive Disease and Surgery Institute, Cleveland, Ohio, USA.
- Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.
- Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
ORCID-Profile: Bryan F Curtin, Satish S C Rao
Zitieren
APA
Curtin, B. F., Quigley, E. M. M., Chey, W. D., Lembo, A. J., Brenner, D. M., Spiegel, B. M. R., & Rao, S. S. C. (2025). The Vibrating Capsule: Safety and Tolerability in Patients With Chronic Idiopathic Constipation. Neurogastroenterology & Motility, 37(5). https://doi.org/10.1111/nmo.15004
Vancouver
Curtin BF, Quigley EMM, Chey WD, Lembo AJ, Brenner DM, Spiegel BMR, et al. The Vibrating Capsule: Safety and Tolerability in Patients With Chronic Idiopathic Constipation. Neurogastroenterology & Motility. 2025;37(5). doi:10.1111/nmo.15004
BibTeX
@article{Curtin2025,
author = {Curtin, Bryan F and Quigley, Eamonn M M and Chey, William D and Lembo, Anthony J and Brenner, Darren M and Spiegel, Brennan M R and Rao, Satish S C},
title = {The Vibrating Capsule: Safety and Tolerability in Patients With Chronic Idiopathic Constipation},
journal = {Neurogastroenterology & Motility},
year = {2025},
volume = {37},
number = {5},
doi = {10.1111/nmo.15004}
}
EUVIMED